Immune off‐target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Immune off‐target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma

Published:2019-02-15 Issue:3 Volume:185 Page:468-479
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Romano Alessandra¹^ORCID,Parrinello Nunziatina L.¹,Chiarenza Annalisa²,Motta Giovanna²,Tibullo Daniele²³,Giallongo Cesarina²,La Cava Piera²,Camiolo Giuseppina²,Puglisi Fabrizio²,Palumbo Giuseppe A.²^ORCID,Di Raimondo Francesco¹²

Affiliation:

1. Section of Haematology Department of General Surgery and Medical‐Surgical Specialties University of Catania Catania Italy

2. Division of Haematology Azienda Policlinico‐OVE Catania Italy

3. Department of Medical and Surgical Sciences and Advanced Technologies “G.F. Ingrassia” University of Catania Catania Italy

Funder

Associazione Italiana Contro le Leucemie - Linfomi e Mieloma

Collegio Ghislieri di Pavia

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15801

Reference32 articles.

1. International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers

2. L-arginine metabolism in myeloid cells controls T-lymphocyte functions

3. CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA

4. Revised Response Criteria for Malignant Lymphoma

5. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab–Vedotin Exert Anti-Lymphoma and Immunostimulating Effects;Cells;2024-05-17

3. Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications;Biology;2023-06-15

4. Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options;Molecular Medicine;2023-03-29

5. Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma;Hematology Reports;2023-03-22